Considering participators' risk bias,which is measured by the method of value at risk,the risk constraints in a two-echelon supply chain coordination under buy-back contract is equal to giving the order of an uppe...Considering participators' risk bias,which is measured by the method of value at risk,the risk constraints in a two-echelon supply chain coordination under buy-back contract is equal to giving the order of an upper bound.With a risk-averse dominant enterprise(M)and a risk-neutral non-dominant one(R),the coordination which optimizes the supply chain under the risk constraints is achieved by a penalty mechanism L to reduce R's order.With risk-neutral M and risk-averse R,M can motivate R to increase his order by providing a risk subsidy K,and two cases are discussed.If the risk constraints of R cannot satisfy M's participation constraint to offer K,M will prefer to accept R's order to obtain a sub-optimization solution of the supply chain.Or else,with M's K,R's optimal order just coordinates the supply chain,which is equal to the case without risk bias,and in this situation R's risk bias only affects the profit distribution between the participators.展开更多
Methodological quality(risk of bias)assessment is an important step before study initiation usage.Therefore,accurately judging study type is the first priority,and the choosing proper tool is also important.In this re...Methodological quality(risk of bias)assessment is an important step before study initiation usage.Therefore,accurately judging study type is the first priority,and the choosing proper tool is also important.In this review,we introduced methodological quality assessment tools for randomized controlled trial(including individual and cluster),animal study,non-randomized interventional studies(including follow-up study,controlled before-and-after study,before-after/pre-post study,uncontrolled longitudinal study,interrupted time series study),cohort study,case-control study,cross-sectional study(including analytical and descriptive),observational case series and case reports,comparative effectiveness research,diagnostic study,health economic evaluation,prediction study(including predictor finding study,prediction model impact study,prognostic prediction model study),qualitative study,outcome measurement instruments(including patient-reported outcome measure development,content validity,structural validity,internal consistency,cross-cultural validity/measurement invariance,reliability,measurement error,criterion validity,hypotheses testing for construct validity,and responsiveness),systematic review and meta-analysis,and clinical practice guideline.The readers of our review can distinguish the types of medical studies and choose appropriate tools.In one word,comprehensively mastering relevant knowledge and implementing more practices are basic requirements for correctly assessing the methodological quality.展开更多
Risk assessment and uncertainty approximation are two major and important parameters that need to be adopted for the development of pharmaceutical process to ensure reliable results.Additionally,there is a need to swi...Risk assessment and uncertainty approximation are two major and important parameters that need to be adopted for the development of pharmaceutical process to ensure reliable results.Additionally,there is a need to switch from the traditional method validation checklist to provide a high level of assurance of method reliability to measure quality attribute of a drug product.In the present work,evaluation of risk profile,combined standard uncertainty and expanded uncertainty in the analysis of acyclovir were studied.Uncertainty was calculated using cause-effect approach,and to make it more accurately applicable a method was validated in our laboratory as per the ICH guidelines.While assessing the results of validation,the calibration model was justified by the lack of fit and Levene's test.Risk profile represents the future applications of this method.In uncertainty the major contribution is due to sample concentration and mass.This work demonstrates the application of theoretical concepts of calibration model tests,relative bias,risk profile and uncertainty in routine methods used for analysis in pharmaceutical field.展开更多
A model of the relationships between individual cognitive biases and individual decision-making based on the analysis of cognitive biases of bonded rationality individual,has been established in this paper by introduc...A model of the relationships between individual cognitive biases and individual decision-making based on the analysis of cognitive biases of bonded rationality individual,has been established in this paper by introducing a set of new variables called overconfidence coefficient and attribution bias coefficient to the sentiment model. The irrational expectation and irrational risk aversion as two inseparable aspects of bonded rationality are expressed in an unified model,and a method of measuring individual cognitive biases is proposed,which overcomes the shortcomings of traditional normative models that can not describe the differences of behaviors among heterogeneous individuals. As a result,numerical simulations show that individual cognitive risk is a positive interaction with overconfidence coefficient,and a negative interaction with attribution bias coefficient.展开更多
Background:Previously published meta-epidemiological studies focused on Western medicine have identified some trial characteristics that impact the treatment effect of randomized controlled trials(RCTs).Nevertheless,i...Background:Previously published meta-epidemiological studies focused on Western medicine have identified some trial characteristics that impact the treatment effect of randomized controlled trials(RCTs).Nevertheless,it remains unclear if similar associations exist in RCTs on Chinese herbal medicine(CHM).Further,Chinese medicine-related characteristics have not been explored yet.Objective:To investigate trial characteristics related to treatment effect estimates on CHM RCTs.Search strategy:This meta-epidemiological study searched 5 databases for systematic reviews on CHM treatment published between January 2011 and July 2021.Inclusion criteria:An eligible systematic review should only include RCTs of CHM and conduct at least one meta-analysis.Data extraction and analysis:Two reviewers independently conducted data extraction on general characteristics of systematic reviews,meta-analyses and included RCTs.They also assessed the risk of bias of RCTs using the Cochrane risk of bias tool.A two-step approach was used for data analyses.The ratio of odds ratios(ROR) and difference in standardized mean differences (dSMD) with 95%confidence interval (CI) were applied to present the difference in effect estimates for binary and continuous outcomes,respectively.Results:Ninety-one systematic reviews,comprising 1338 RCTs were identified.For binary outcomes,RCTs incorporated with syndrome differentiation (ROR:1.23;95%CI:[1.07,1.39]),adopting Chinese medicine formula (ROR:1.19;95%CI:[1.03,1.34]),with low risk of bias on incomplete outcome data (ROR:1.29;95%CI:[1.06,1.52]) and selective outcome reporting (ROR:1.12;95%CI:[1.01,1.24]),as well as a trial size≥100 (ROR:1.23;95%CI:[1.04,1.42]) preferred to show larger effect estimates.As for continuous outcomes,RCTs with Chinese medicine diagnostic criteria (dSMD:0.23;95%CI:[0.06,0.41]),judged as high/unclear risk of bias on allocation concealment (dSMD:-0.70;95%CI:[-0.99,-0.42]),with low risk of bias on incomplete outcome data (dSMD:0.30;95%CI:[0.18,0.43]),conducted at a single center (dSMD:-0.33;95%CI:[-0.61,-0.05]),not using intention-to-treat analysis (dSMD:-0.75;95%CI:[-1.43,-0.07]),and without funding support (dSMD:-0.22;95%CI:[-0.41,-0.02]) tended to show larger effect estimates.Conclusion:This study provides empirical evidence for the development of a specific critical appraisal tool for risk of bias assessments on CHM RCTs.展开更多
Objective:Heterogeneity of participants in clinical trials distorts intervention efficacy.However,factors associated with participant heterogeneity in randomized clinical trials(RCTs)focusing on systemic sclerosis(SSc...Objective:Heterogeneity of participants in clinical trials distorts intervention efficacy.However,factors associated with participant heterogeneity in randomized clinical trials(RCTs)focusing on systemic sclerosis(SSc)are not clear.We conducted this systematic review to establish normative standards for future research and help develop management guidelines.Methods:Three databases and 4 registries were searched to identify characteristics of SSc RCTs across different countries.Risk of bias was assessed by the Cochrane Collaboration’s tool and logistic regression was performed to calculate crude and adjusted odds ratios.Results:In total,261 trials met our inclusion criteria.The quality of SSc RCTs worldwide was relatively poor,with no trend of improvement in recent years,and only 12.2%were ranked as having a low risk of bias.Trials with a low risk of bias as well as single-center,single-country,or open-label trials tended to have better participant adherence than trials with a high risk of bias and multiple-center,multiple-country,or double-blind trials.Interestingly,trial registration and primary outcome definition contributed to high withdrawal.National income was also relevant;participant adherence in high-income countries,but not in upper-and lower-middle-income countries,was significantly altered by different variables.Conclusion:Overall,the risk of bias,national income,and trial design may lead to participant heterogeneity of SSc RCTs and ultimately confound the general clinical utility of the results.Trials with a rigorous design and transparent conduction protocol are crucial for obtaining unbiased data that can serve as a reference and for maintaining the fundamental repeatability of SSc RCTs.展开更多
A novel biased proportional navigation guidance (BPNG) law is proposed for the close approach phase, which aims to make the spacecraft rendezvous with the target in specific relative range and direction. Firstly, in...A novel biased proportional navigation guidance (BPNG) law is proposed for the close approach phase, which aims to make the spacecraft rendezvous with the target in specific relative range and direction. Firstly, in order to describe the special guidance requirements, the concept of zero effort miss vector is proposed and the dangerous area where there exists collision risk for safety consideration is defined. Secondly, the BPNG, which decouples the range control and direc- tion control, is designed in the line-of-sight (LOS) rotation coordinate system. The theoretical anal- ysis proves that BPNG meets guidance requirements quite well. Thirdly, for the consideration of fuel consumption, the optimal biased proportional navigation guidance (OBPNG) law is derived by solving the Schwartz inequality. Finally, simulation results show that BPNG is effective for the close approach with the ability of evading the dangerous area and OBPNG consumes less fuel compared with BPNG.展开更多
基金The National Natural Science Foundation of China(No.70671025)the National Key Technology R&D Program of China during the 11th Five-Year Plan Period(No.2006BAH02A06)
文摘Considering participators' risk bias,which is measured by the method of value at risk,the risk constraints in a two-echelon supply chain coordination under buy-back contract is equal to giving the order of an upper bound.With a risk-averse dominant enterprise(M)and a risk-neutral non-dominant one(R),the coordination which optimizes the supply chain under the risk constraints is achieved by a penalty mechanism L to reduce R's order.With risk-neutral M and risk-averse R,M can motivate R to increase his order by providing a risk subsidy K,and two cases are discussed.If the risk constraints of R cannot satisfy M's participation constraint to offer K,M will prefer to accept R's order to obtain a sub-optimization solution of the supply chain.Or else,with M's K,R's optimal order just coordinates the supply chain,which is equal to the case without risk bias,and in this situation R's risk bias only affects the profit distribution between the participators.
基金supported(in part)by the Entrusted Project of National commission on health and health of China(No.2019099)the National Key Research and Development Plan of China(2016YFC0106300)the Nature Science Foundation of Hubei Province(2019FFB03902)。
文摘Methodological quality(risk of bias)assessment is an important step before study initiation usage.Therefore,accurately judging study type is the first priority,and the choosing proper tool is also important.In this review,we introduced methodological quality assessment tools for randomized controlled trial(including individual and cluster),animal study,non-randomized interventional studies(including follow-up study,controlled before-and-after study,before-after/pre-post study,uncontrolled longitudinal study,interrupted time series study),cohort study,case-control study,cross-sectional study(including analytical and descriptive),observational case series and case reports,comparative effectiveness research,diagnostic study,health economic evaluation,prediction study(including predictor finding study,prediction model impact study,prognostic prediction model study),qualitative study,outcome measurement instruments(including patient-reported outcome measure development,content validity,structural validity,internal consistency,cross-cultural validity/measurement invariance,reliability,measurement error,criterion validity,hypotheses testing for construct validity,and responsiveness),systematic review and meta-analysis,and clinical practice guideline.The readers of our review can distinguish the types of medical studies and choose appropriate tools.In one word,comprehensively mastering relevant knowledge and implementing more practices are basic requirements for correctly assessing the methodological quality.
文摘Risk assessment and uncertainty approximation are two major and important parameters that need to be adopted for the development of pharmaceutical process to ensure reliable results.Additionally,there is a need to switch from the traditional method validation checklist to provide a high level of assurance of method reliability to measure quality attribute of a drug product.In the present work,evaluation of risk profile,combined standard uncertainty and expanded uncertainty in the analysis of acyclovir were studied.Uncertainty was calculated using cause-effect approach,and to make it more accurately applicable a method was validated in our laboratory as per the ICH guidelines.While assessing the results of validation,the calibration model was justified by the lack of fit and Levene's test.Risk profile represents the future applications of this method.In uncertainty the major contribution is due to sample concentration and mass.This work demonstrates the application of theoretical concepts of calibration model tests,relative bias,risk profile and uncertainty in routine methods used for analysis in pharmaceutical field.
基金Sponsored by the National Natural Science Foundation of China (Grant No 70903016)the Doctoral Funds of the Ministry of Education(Grant No0070213008)Social Sciences of the National Education Ministry of China Grant (Grant No 07JC630027)
文摘A model of the relationships between individual cognitive biases and individual decision-making based on the analysis of cognitive biases of bonded rationality individual,has been established in this paper by introducing a set of new variables called overconfidence coefficient and attribution bias coefficient to the sentiment model. The irrational expectation and irrational risk aversion as two inseparable aspects of bonded rationality are expressed in an unified model,and a method of measuring individual cognitive biases is proposed,which overcomes the shortcomings of traditional normative models that can not describe the differences of behaviors among heterogeneous individuals. As a result,numerical simulations show that individual cognitive risk is a positive interaction with overconfidence coefficient,and a negative interaction with attribution bias coefficient.
基金supported by the National Natural Science Foundation of China (No.81973709)Chinese Medicine Development Fund (21B2/018A)State Key Laboratory of Dampness Syndrome of Chinese Medicine Special Fund (SZ2021ZZ05,SZ2021ZZ0502)。
文摘Background:Previously published meta-epidemiological studies focused on Western medicine have identified some trial characteristics that impact the treatment effect of randomized controlled trials(RCTs).Nevertheless,it remains unclear if similar associations exist in RCTs on Chinese herbal medicine(CHM).Further,Chinese medicine-related characteristics have not been explored yet.Objective:To investigate trial characteristics related to treatment effect estimates on CHM RCTs.Search strategy:This meta-epidemiological study searched 5 databases for systematic reviews on CHM treatment published between January 2011 and July 2021.Inclusion criteria:An eligible systematic review should only include RCTs of CHM and conduct at least one meta-analysis.Data extraction and analysis:Two reviewers independently conducted data extraction on general characteristics of systematic reviews,meta-analyses and included RCTs.They also assessed the risk of bias of RCTs using the Cochrane risk of bias tool.A two-step approach was used for data analyses.The ratio of odds ratios(ROR) and difference in standardized mean differences (dSMD) with 95%confidence interval (CI) were applied to present the difference in effect estimates for binary and continuous outcomes,respectively.Results:Ninety-one systematic reviews,comprising 1338 RCTs were identified.For binary outcomes,RCTs incorporated with syndrome differentiation (ROR:1.23;95%CI:[1.07,1.39]),adopting Chinese medicine formula (ROR:1.19;95%CI:[1.03,1.34]),with low risk of bias on incomplete outcome data (ROR:1.29;95%CI:[1.06,1.52]) and selective outcome reporting (ROR:1.12;95%CI:[1.01,1.24]),as well as a trial size≥100 (ROR:1.23;95%CI:[1.04,1.42]) preferred to show larger effect estimates.As for continuous outcomes,RCTs with Chinese medicine diagnostic criteria (dSMD:0.23;95%CI:[0.06,0.41]),judged as high/unclear risk of bias on allocation concealment (dSMD:-0.70;95%CI:[-0.99,-0.42]),with low risk of bias on incomplete outcome data (dSMD:0.30;95%CI:[0.18,0.43]),conducted at a single center (dSMD:-0.33;95%CI:[-0.61,-0.05]),not using intention-to-treat analysis (dSMD:-0.75;95%CI:[-1.43,-0.07]),and without funding support (dSMD:-0.22;95%CI:[-0.41,-0.02]) tended to show larger effect estimates.Conclusion:This study provides empirical evidence for the development of a specific critical appraisal tool for risk of bias assessments on CHM RCTs.
基金funding received from the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences(No.2020-RC320-003)the National Natural Science Foundation of China(No.81830097)
文摘Objective:Heterogeneity of participants in clinical trials distorts intervention efficacy.However,factors associated with participant heterogeneity in randomized clinical trials(RCTs)focusing on systemic sclerosis(SSc)are not clear.We conducted this systematic review to establish normative standards for future research and help develop management guidelines.Methods:Three databases and 4 registries were searched to identify characteristics of SSc RCTs across different countries.Risk of bias was assessed by the Cochrane Collaboration’s tool and logistic regression was performed to calculate crude and adjusted odds ratios.Results:In total,261 trials met our inclusion criteria.The quality of SSc RCTs worldwide was relatively poor,with no trend of improvement in recent years,and only 12.2%were ranked as having a low risk of bias.Trials with a low risk of bias as well as single-center,single-country,or open-label trials tended to have better participant adherence than trials with a high risk of bias and multiple-center,multiple-country,or double-blind trials.Interestingly,trial registration and primary outcome definition contributed to high withdrawal.National income was also relevant;participant adherence in high-income countries,but not in upper-and lower-middle-income countries,was significantly altered by different variables.Conclusion:Overall,the risk of bias,national income,and trial design may lead to participant heterogeneity of SSc RCTs and ultimately confound the general clinical utility of the results.Trials with a rigorous design and transparent conduction protocol are crucial for obtaining unbiased data that can serve as a reference and for maintaining the fundamental repeatability of SSc RCTs.
基金co-supported by the National Natural Science Foundation of China(No.11372345)the National Basic Research Program of China(No.2013CB733100)
文摘A novel biased proportional navigation guidance (BPNG) law is proposed for the close approach phase, which aims to make the spacecraft rendezvous with the target in specific relative range and direction. Firstly, in order to describe the special guidance requirements, the concept of zero effort miss vector is proposed and the dangerous area where there exists collision risk for safety consideration is defined. Secondly, the BPNG, which decouples the range control and direc- tion control, is designed in the line-of-sight (LOS) rotation coordinate system. The theoretical anal- ysis proves that BPNG meets guidance requirements quite well. Thirdly, for the consideration of fuel consumption, the optimal biased proportional navigation guidance (OBPNG) law is derived by solving the Schwartz inequality. Finally, simulation results show that BPNG is effective for the close approach with the ability of evading the dangerous area and OBPNG consumes less fuel compared with BPNG.